Kearney Jessica, Gnudi Luigi
Department of Diabetes and Endocrinology, Guy's and St Thomas NHS Foundation Trust, London SE1 9RT, UK.
School of Cardiovascular and Metabolic Medicine & Sciences, British Heart Foundation Centre of Research Excellence, Faculty of Life Sciences & Medicine, King's College London, London WC2R 2LS, UK.
Pharmaceutics. 2023 Apr 27;15(5):1343. doi: 10.3390/pharmaceutics15051343.
The diabetes epidemic and the increasing number of patients with diabetic chronic vascular complications poses a significant challenge to health care providers. Diabetic kidney disease is a serious diabetes-mediated chronic vascular complication and represents a significant burden for both patients and society in general. Diabetic kidney disease not only represents the major cause of end stage renal disease but is also paralleled by an increase in cardiovascular morbidity and mortality. Any interventions to delay the development and progression of diabetic kidney disease are important to reduce the associated cardiovascular burden. In this review we will discuss five therapeutic tools for the prevention and treatment of diabetic kidney disease: drugs inhibiting the renin-angiotensin-aldosterone system, statins, the more recently recognized sodium-glucose co-transporter-2 inhibitors, glucagon-like peptide 1 agonists, and a novel non-steroidal selective mineralocorticoid receptor antagonist.
糖尿病的流行以及糖尿病慢性血管并发症患者数量的增加给医疗服务提供者带来了重大挑战。糖尿病肾病是一种由糖尿病介导的严重慢性血管并发症，对患者和整个社会来说都是一个重大负担。糖尿病肾病不仅是终末期肾病的主要原因，还伴随着心血管发病率和死亡率的上升。任何延缓糖尿病肾病发生和发展的干预措施对于减轻相关的心血管负担都很重要。在这篇综述中，我们将讨论预防和治疗糖尿病肾病的五种治疗手段：抑制肾素-血管紧张素-醛固酮系统的药物、他汀类药物、最近被认可的钠-葡萄糖协同转运蛋白2抑制剂、胰高血糖素样肽1激动剂以及一种新型非甾体选择性盐皮质激素受体拮抗剂。
